Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
---|---|---|---|---|---|
07/27/2022 | 104.08% | Ladenburg Thalmann | → $6 | Initiates Coverage On | → Buy |
05/25/2021 | 410.2% | Benchmark | → $15 | Initiates Coverage On | → Buy |
Anebulo Pharmaceuticals Questions & Answers
The latest price target for Anebulo Pharmaceuticals (NASDAQ: ANEB) was reported by Ladenburg Thalmann on July 27, 2022. The analyst firm set a price target for $6.00 expecting ANEB to rise to within 12 months (a possible 104.08% upside). 1 analyst firms have reported ratings in the last year.
The latest analyst rating for Anebulo Pharmaceuticals (NASDAQ: ANEB) was provided by Ladenburg Thalmann, and Anebulo Pharmaceuticals initiated their buy rating.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Anebulo Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Anebulo Pharmaceuticals was filed on July 27, 2022 so you should expect the next rating to be made available sometime around July 27, 2023.
While ratings are subjective and will change, the latest Anebulo Pharmaceuticals (ANEB) rating was a initiated with a price target of $0.00 to $6.00. The current price Anebulo Pharmaceuticals (ANEB) is trading at is $2.94, which is within the analyst's predicted range.